Marksans Pharma Ltd. (MARKSANS): Marksans Pharma Share Price rises 3.32% near 52-week high
- September 23, 2026
- Posted by: Harsh Piplani
- Category: News
Marksans Pharma Share Price is Rs 343.65, up 3.32%, and trading near its 52-week high. The company’s market capitalisation stands at Rs 15,323.73 Cr as of 23 September 2026 at 2:48 PM IST.
Marksans Pharma Share Price is trading at Rs 343.65, up Rs 11.05 from the previous close of Rs 332.60, and remains close to its 52-week high after touching Rs 345 during the latest market update. The company’s market capitalisation is Rs 15,323.73 Cr, placing the move in a sizeable listed-company context within the healthcare space. According to the latest Univest figures, the price event is clear, but the data does not establish a company-specific catalyst. That makes Marksans Pharma Stock News relevant today for readers tracking Marksans Pharma Share Price Today, recent price behaviour and the valuation backdrop behind the move.
Marksans Pharma Share Price Today: Price Action Analysis
The share opened at Rs 333.45 and traded between Rs 331.25 and Rs 345 in the latest update. Turnover stood at Rs 3.82 Cr. Marksans Pharma Share Price therefore sits close to its yearly high and is being tracked by investors who want to see whether the current level holds as the market digests the latest Marksans Pharma Share Price Update.
| Metric | Value |
|---|---|
| Current Price | Rs 343.65 |
| Previous Close | Rs 332.6 |
| Today's Move | +Rs 11.05 (+3.32%) |
| Open | Rs 333.45 |
| High | Rs 345 |
| Low | Rs 331.25 |
| Turnover | Rs 3.82 crore |
| Market Capitalisation | Rs 15,323.73 crore |
Marksans Pharma Ltd. (MARKSANS) traded at Rs 343.65 versus the previous close of Rs 332.6, a rise of 3.32%. The stock opened at Rs 333.45, reached a high of Rs 345 and touched a low of Rs 331.25.
Marksans Pharma Share Price Today shows a firm session so far, with the stock at Rs 343.65 against a previous close of Rs 332.60. That is a gain of Rs 11.05, or 3.32%, while the day’s range of Rs 331.25 to Rs 345 shows the stock moving within a relatively tight band around its recent high. The day opened at Rs 333.45, and turnover was Rs 3.82 Cr in the latest update.
What happened today is straightforward: Marksans Pharma Share Price stayed close to its 52-week high zone and continued to trade near the top end of the day’s range. The latest Univest data confirms the price event, but it does not establish a company-specific catalyst. For readers scanning Marksans Pharma Stock News or Marksans Pharma Share News, the key takeaway is the proximity to the one-year high and the continued focus on how price behaves around that area.
Marksans Pharma Ltd. (MARKSANS) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 15,323.73 crore |
| P/E Ratio | 29.17x |
| P/B Ratio | 4.74x |
| ROE | 15.31% |
| ROCE | 21.1% |
| EPS | Rs 11.4 |
| Book Value Per Share | Rs 70.16 |
| Dividend Yield | 0.27% |
Marksans Pharma Ltd. (MARKSANS) fundamental metrics show P/E 29.17x, P/B 4.74x, ROE 15.31%, ROCE 21.1%. These figures provide context only and are not a buy or sell signal.
Marksans Pharma Ltd. has a market capitalisation of Rs 15323.73 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 29.17x, P/B at 4.74x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 15.31% and ROCE of 21.1%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 11.4, book value per share of Rs 70.16, dividend yield of 0.27%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 28.33x, median ROE of 11.69%, median ROCE of 13.32%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 29.17x |
| Benchmark Median P/E | 28.33x |
| Benchmark Average P/E | 41.93x |
| Benchmark P/E Range | 0x to 765.12x |
| Company P/B Ratio | 4.74x |
| Benchmark Median P/B | 2.96x |
| Company ROE | 15.31% |
| Benchmark Median ROE | 11.69% |
| Company ROCE | 21.1% |
| Benchmark Median ROCE | 13.32% |
| Company Market Capitalisation | Rs 15,323.73 crore |
| Benchmark Median Market Cap | Rs 718.76 crore |
Marksans Pharma Ltd. (MARKSANS) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Marksans Pharma Ltd. (MARKSANS) has a P/E ratio of 29.17x, which is above the benchmark median of 28.33x, a difference of +2.97%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Marksans Pharma Ltd. (MARKSANS) has a ROE of 15.31%, which is above the benchmark median of 11.69%, a difference of +30.97%. Marksans Pharma Ltd. (MARKSANS) has a ROCE of 21.1%, which is above the benchmark median of 13.32%, a difference of +58.41%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Natco Pharma Ltd. | NATCOPHARM | 14,624.32 | 12.76 | 1.56 | 16.3 | 17.16 |
| Concord Biotech Ltd. | CONCORDBIO | 16,537.21 | 58.15 | 7.72 | 13.54 | 18.04 |
| Alembic Pharmaceuticals Ltd. | APLLTD | 16,714.75 | 23.82 | 2.83 | 12.35 | 11.74 |
| Jubilant Pharmova Ltd. | JUBLPHARMA | 16,715.76 | 48.44 | 2.39 | 5.97 | 8.69 |
| Astrazeneca Pharma India Ltd. | ASTRAZEN | 16,780.38 | 98.93 | 18.56 | 23.02 | 31.24 |
Marksans Pharma Ltd. (MARKSANS) has a P/E ratio of 29.17x compared with the displayed peer median of 48.44x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 15.31% compares with a peer median of 13.54% across the companies shown in the table. ROCE stood at 21.1% versus the displayed peer median of 17.16%, providing a capital-efficiency comparison. Marksans Pharma Ltd. (MARKSANS) has a market capitalisation of Rs 15,323.73 crore. Among the 5 peers shown, 4 have a larger market capitalisation.
Why Investors Are Watching Marksans Pharma
- Marksans Pharma Share Price is at Rs 343.65, up 3.32% from the previous close.
- The stock touched Rs 345 in the latest market update, keeping it near its 52-week high.
- Market capitalisation stands at Rs 15,323.73 Cr, placing the company in a large listed-company bracket by scale.
- P/E is 29.17 and P/B is 4.74, both useful for Marksans Pharma Share Price analysis against peers.
- ROE is 15.31%, ROCE is 21.1%, EPS is Rs 11.4 and book value is Rs 70.16, which adds context to Marksans Pharma Fundamental Analysis.
About Marksans Pharma
Marksans Pharma Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The company is tracked in NSE and BSE market context under the symbol MARKSANS. Marksans Pharma Share Price is being watched today because the stock is trading near its 52-week high while the company’s reported financial metrics, valuation and sector positioning remain part of the broader Marksans Pharma Stock News narrative. The latest Univest overview keeps the focus on the listed business, its market capitalisation and the reported results series.
Frequently Asked Questions
Why is Marksans Pharma Share Price in focus today?
Ans. Marksans Pharma Share Price is in focus because it is trading at Rs 343.65, up 3.32%, and remains near its 52-week high. The latest Univest data confirms the price event without assigning a specific catalyst.
What is the current Marksans Pharma Share Price today?
Ans. Marksans Pharma Share Price is Rs 343.65 in the latest update. It is above the previous close of Rs 332.60 and has moved within a day range of Rs 331.25 to Rs 345.
How close is Marksans Pharma Share Price to its yearly high?
Ans. Marksans Pharma Share Price is close to its 52-week high after touching Rs 345 in the latest market update. That keeps the stock near its yearly peak zone rather than far below it.
What does the market capitalisation of Marksans Pharma indicate?
Ans. Marksans Pharma has a market capitalisation of Rs 15,323.73 Cr. Market capitalisation reflects company size in the listed market, and it also helps compare the stock with peers and industry benchmarks.
What do the valuation ratios show for Marksans Pharma Share Price?
Ans. Marksans Pharma trades at a P/E of 29.17 and a P/B of 4.74. Against the same-industry benchmark, both ratios sit above the median, which adds valuation context to Marksans Pharma Share Price.
How strong are the return ratios in Marksans Pharma Fundamental Analysis?
Ans. Marksans Pharma reports ROE of 15.31% and ROCE of 21.1%. Both are above the industry medians in the same-industry benchmark, which gives useful context for Marksans Pharma Share Price.
What do EPS and book value say about Marksans Pharma?
Ans. EPS is Rs 11.4 and book value is Rs 70.16. EPS reflects earnings per share, while book value shows accounting net worth per share, both important in Marksans Pharma Share Price analysis.
How does Marksans Pharma compare with listed peers?
Ans. Marksans Pharma sits between lower-valued peers like Natco Pharma and higher-valued names like Concord Biotech and Astrazeneca Pharma India. Its ROE and ROCE are also competitive within the latest Univest peer set.
Track Marksans Pharma Share Price on Univest
Use Marksans Pharma Ltd. (MARKSANS) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Track Marksans Pharma Share Price on Univest for live price updates, company news, fundamental ratios, sector context and 52-week levels. Univest also helps readers follow Marksans Pharma Share Price Today, Marksans Pharma Latest News, Marksans Pharma Financial Results and Marksans Pharma Stock Analysis in one place.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
